Axsome Therapeutics, Inc. Q2 2026 revenue reached $218M, a 46% increase driven by Ovelity's strong market performance. Learn more about their financials and future outlook.
Axsome Therapeutics, Inc. reported Q2 2026 revenue of $218 million, a 46% increase year-over-year and significantly above the $150 million consensus estimate. This robust growth was primarily driven by the strong commercial performance of its product Ovelity, particularly in the newly launched Alzheimer's Disease agitation market.
Key Takeaways
- Net product revenue reached $218 million, up 46% year-over-year, driven by Ovelity and Sanozi growth.
- Ovelity sales for the quarter were $180.3 million, an increase of 51% YoY and 18% QoQ, reflecting strong demand.
- Total prescriptions for Ovelity increased 34% YoY, with notable growth in the elderly demographic, indicating market adoption.
- Net loss for the quarter was $51.3 million or $0.99 per share, slightly higher than the net loss of $48 million or $0.97 per share for Q2 2025.
- Cash and cash equivalents at the end of Q2 stood at approximately $320 million, indicating sufficient liquidity to fund operations through anticipated cash flow positivity.
Strong Product Performance Drives Revenue Growth
Axsome's revenue increase in Q2 2026 to $218 million was fueled by exceptional sales from its flagship product, Ovelity. The company reported net product sales of $180.3 million for Ovelity, marking a substantial 51% increase compared to $119.5 million in the same quarter last year. Additionally, Ovelity's sales grew 18% sequentially from Q1 2026, indicating a strong ramp-up in market demand following the expansion of its sales force and the launch in the Alzheimer's agitation market.
| Metric | Q2 2026 | YoY | QoQ |
|---|---|---|---|
| Revenue | $218M | +46% | N/A |
| Ovelity Sales | $180.3M | +51% | +18% |
| Simbravo Sales | $2.3M | N/A | N/A |
| Sanozi Sales | $35.8M | +20% | N/A |
Ovelity Launch in Alzheimer's Disease Agitation Shows Promise
The launch of Ovelity for the treatment of Alzheimer's Disease agitation has proven successful within the first two months, with NuBran prescriptions increasing by 126% in patients aged 65 and older. This growth reflects both the effectiveness of the expanded sales force and the favorable reception from prescribers. According to Ari Maisel, Chief Commercial Officer, “We are excited by the initial feedback that we have received from prescribers, which includes positive anecdotal evidence of Ovelity's differentiated clinical profile.” The uptake in long-term care settings has also been encouraging, although the company anticipates sharing more specific data as the launch progresses.
Increased Investment in Commercialization
Axsome's selling, general, and administrative expenses rose to $208.1 million in Q2 from $130.3 million in the previous year, driven by heightened commercialization activities for Ovelity and Simbravo. Despite the increased expenses, the company maintains that it is improving operating leverage, as indicated by a 14% revenue growth against a 7% increase in operating expenses. The company aims to sustain this momentum as it navigates the rest of 2026, leveraging its strong cash position to invest in growth initiatives.
Guidance and Future Outlook
Axsome did not provide specific guidance for Q3 or beyond in terms of revenue or EPS, but management expressed optimism about ongoing sales growth, particularly for Ovelity, as it gains acceptance in new markets. They indicated that cash reserves are adequate to support operations into cash flow positivity, which is a critical benchmark for long-term sustainability. The company is also focused on expanding market access and improving payer coverage, which currently stands at 89% for Ovelity across channels.
Frequently Asked Questions
Did Axsome Therapeutics, Inc beat earnings estimates in Q2 2026?
Yes, Axsome reported a revenue of $218 million, surpassing the consensus estimate of $150 million.
What was the net loss for Axsome Therapeutics in Q2 2026?
The net loss for the quarter was $51.3 million, or $0.99 per share, compared to a net loss of $48 million, or $0.97 per share in Q2 2025.
How did Ovelity perform in the quarter?
Ovelity generated $180.3 million in sales, a 51% increase year-over-year and an 18% increase from the previous quarter.
What is Axsome's cash position as of Q2 2026?
Axsome Therapeutics ended Q2 2026 with approximately $320 million in cash and cash equivalents, sufficient to fund operations into cash flow positivity.
The outcome of this quarter sets Axsome on a path of growth, but investor focus will remain on the sustainability of Ovelity's momentum and the broader implications for its pipeline and commercialization strategies moving forward.
This analysis is based on public earnings call materials and is not investment advice.
